Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Announces Pricing of $650 Million Public Offering
Summary
Terns Pharmaceuticals, Inc. announced on December 9, 2025, the pricing of its upsized underwritten public offering of 16,250,000 shares of common stock at $40.00 per share, with an additional option for underwriters to purchase 2,437,500 shares. The company estimates net proceeds of approximately $705.8 million, which will be used for research, clinical trials, development, manufacturing, and working capital. The offering is expected to close on December 11, 2025.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement